Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02490930 : A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
PhaseEarly Phase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Gender: Male and Female

- Age: Patients must be at least 18 years of age.

- Race: Minorities will be recruited. No exclusion to this study will be based on race.

- Patients must have histologically confirmed high grade astrocytoma, WHO grade III or
IV, by pathology.

- Patients' proposed post-operative treatment plan must include standard focal brain
irradiation and temozolomide.

- Patients must have a Karnofsky Performance Status > 60 % (i.e. the patient must be
able to care for himself/herself with occasional help from others).

- Patients must have normal bone marrow function, with a baseline total lymphocyte
count > 1000.

- Patients must be able to provide informed consent.

- Glucocorticoid use is allowed.

- Women of childbearing potential should use effective contraception during and for two
months after stopping fingolimod.

Exclusion Criteria:

- Patients must not have received prior radiation therapy, chemotherapy, immunotherapy,
therapy with biologic agents or hormonal therapy for their brain tumor.

- Patients must not have recent (within six months) occurrence of myocardial
infarction, unstable angina, stroke, transient ischemic attack, decompensated heart
failure requiring hospitalization, or Class III/IV heart failure.

- Patients must not have history of or presence of Mobitz Type II 2nd degree or 3rd
degree atrioventricular block or sick sinus syndrome, unless patient has a pacemaker.

- Patients must not have baseline QTc interval > 500 ms.

- Patients must not be on treatment with Class Ia or Class III antiarrhythmic drugs.

- Patients must not have a history of macular edema, uveitis or diabetes mellitus.

- Patients must not have elevated liver transaminase levels. Adequate liver function is
defined as total bilirubin < 1.5 times upper limit of normal, SGPT (ALT) < 5 times
upper limit of normal and serum albumin > 2 g/dL.

- Patients must not have an active infection.

- Patients with known HIV will be excluded.

- Patients with collagen vascular disease are excluded.

- Patients taking immunosuppressive medications (other than dexamethasone) will be
excluded.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02490930      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740